This study investigated the prevalence and impact of auditory agnosia for environmental sounds in individuals with Alzheimer’s disease (AD), finding that over half exhibited signs of this central auditory dysfunction along with a high rate of unrecognized peripheral hearing loss. Although these factors appeared independent and showed limited direct effect on measured quality of life, possibly due to sheltered living environments and lack of patient awareness, they jointly contribute to daily functional decline, highlighting the importance of early hearing assessment and intervention in AD management.

The article discusses the need for and challenges of developing combination therapies for Alzheimer's disease, given the complex and multifactorial nature of the disease. As of 2024, there were 21 combination trials in the pipeline, primarily involving repurposed agents targeting processes like inflammation, senescence, and amyloid-tau interactions. Key challenges include distinguishing individual drug effects and managing the operational complexity of combination trials.f

This article provides a narrative review of the relationships between modifiable lifestyle factors and plasma biomarkers of Alzheimer's disease (AD). The key findings are that better nutrition, more physical activity, and good sleep quality are associated with more favorable plasma AD biomarker profiles, potentially reflecting less cerebral AD pathology.

The article discusses the potential of glucagon-like peptide-1 (GLP-1) receptor agonists (GRA) as novel therapeutic agents for neurodegenerative diseases (NDs) like Alzheimer's disease (AD) and Parkinson's disease (PD). GRA have shown promising effects in modulating neuroinflammation, oxidative stress, mitochondrial and autophagic functions, and protein misfolding in preclinical studies. Clinical trials have demonstrated that GRA like exenatide, liraglutide, and lixisenatide can improve motor deficits in PD and cognitive function in AD patients.